MET:NYSEMetLife, Inc. Analysis
Data as of 2026-08-22 - not real-time
$94.34
Latest Price
3/10Risk
Risk Level: Low
Executive Summary
The moving-average structure behind MetLife, Inc. is bullish at $94.34, with short-term averages leading the long-term ones. The last 30 days have gained 2.9%. With RSI at 47.5 the momentum picture is neutral, alongside a bearish MACD signal. Watch $93.37 as support and $100.93 as the nearer resistance level.
Valuation screens as fair: a P/E of 18.1 sits in line with the sector average of 16.8. Consensus targets land 10.6% above where the shares trade now. Revenue is growing at 10.5% on a 4.6% profit margin. The 2.51% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 20.5%, a beta of 0.69 and a maximum drawdown of 18.3%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 4/10 conviction on the long call.
Valuation screens as fair: a P/E of 18.1 sits in line with the sector average of 16.8. Consensus targets land 10.6% above where the shares trade now. Revenue is growing at 10.5% on a 4.6% profit margin. The 2.51% dividend yield looks covered by current payout levels.
Risk scores 3 out of 10, which is low for this asset class. With 30-day volatility of 20.5%, a beta of 0.69 and a maximum drawdown of 18.3%, the drawdown profile is forgiving relative to most of the market. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — buy short-term against hold longer out, with 4/10 conviction on the long call.
Top Market Events
MetLife NYSE: MET announced that its board of directors has approved a new US$3b share repurchase authorization.Global insurance giant MetLife NYSE:MET in Q2 CY2026, but sales rose 6.MetLife stock keeps investors focused on the insurer's latest reported earnings, capital position, a
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 5/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 81.03
- MACD momentum is negative
Medium Term
1–3 yearsPositive
Model confidence: 5/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 18.1 versus sector average of 16.8
- Trading above the 200-day average of 81.03
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- P/E of 18.1 versus sector average of 16.8
- Analyst targets imply +10.6% versus the current price
- Revenue growth of +10.5%
Key Metrics & Analysis
Financial Health
Revenue Growth10.50%
Profit Margin4.57%
P/E Ratio18.1
ROE13.09%
ROA0.45%
Debt/Equity179.93
P/B Ratio2.2
Op. Cash Flow$15.6B
Free Cash Flow$-20953999360
Industry P/E16.8
Technical Analysis
TrendBullish
RSI47.5
Support$93.37
Resistance$100.93
MA 20$96.56
MA 50$92.41
MA 200$81.03
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41
Valuation
Fair Value$304.89
Target Price$104.38
Upside/Downside10.64%
GradeFair
TypeBlend
Dividend Yield2.51%
Risk Assessment
Beta0.69
Volatility20.50%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.